SD-169 (Standaard)

SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation[1].

1670-87-7

12352005

P38 MAPK

MAPK/ERK Pathway

Metabolic Disease

O=C(C1=CC2=C(NC=C2)C=C1)N

C9H8N2O

160.18

[1]Medicherla S, et al. Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes. J Pharmacol Exp Ther. 2006 Jul;318 (1) :99-107.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W015445R/

Reference Standards